XTAMPZA ER
Peakoxycodone
NDAORALCAPSULE, EXTENDED RELEASE
Approved
Apr 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
XTAMPZA ER (oxycodone) is full opioid agonists [moa]. First approved in 2016.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XTAMPZA ER is an extended-release oral capsule formulation of oxycodone, a full opioid agonist approved by the FDA in April 2016. It is indicated for the management of severe pain sufficient to require opioid treatment when alternative therapies are inadequate. The product delivers oxycodone through an extended-release mechanism designed to provide sustained analgesia, positioning it within the chronic pain management segment of the opioid market.
$0.3BPart D
10.3 years to LOEMechanism of Action
Full Opioid Agonists
Pharmacologic Class:
Opioid Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)
Started Nov 2024
30 enrolled
Pharmacokinetics
Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)
Started Dec 2021
111 enrolled
Pharmacokinetics
PG and PK of Oxycodone to Personalize Post-op Pain Management Following Surgery in Children
Started Apr 2018
129 enrolled
Postoperative PainOpioid Dependence
Cannabis Versus Oxycodone for Pain Relief
Started Jun 2017
33 enrolled
Back PainNeck Pain
An Open Label, Prospective Study of the Analgesic Efficacy of Oral Xartemis Compared to Generic Oxycodone/APAP( Acetaminophen) in the Treatment of Moderate to Severe Post Operative Pain.
Started May 2014
114 enrolled
Post Operative Pain
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.